Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20428422 | 0.86 | NQO1 (0.49) | PTGESALOX5LCKABCG2ALDH1A1 | |
| SCHEMBL20420805 | 0.85 | ALDH1A1 (0.51) | ABCG2CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL20420716 | 0.84 | ALDH1A1 (0.52) | CYP1A1CYP1B1ALDH1A1HPGDKMT2A | |
| SCHEMBL20420788 | 0.82 | ALDH1A1 (0.61) | ABCG2ALDH1A1HPGDKMT2AKDM4E | |
| SCHEMBL20420768 | 0.81 | ABCG2 (0.47) | PTGESALOX5LCKABCG2CYP1A1 | |
| SCHEMBL20420777 | 0.80 | CA9 (0.54) | ABCG2CYP1A1CYP1B1HPGDKMT2A | |
| SCHEMBL9528168 | 0.78 | LCK (0.78) | PTGESALOX5LCKABCG2CYP1A1 | |
| SCHEMBL20420761 | 0.78 | MAOB (0.58) | ABCG2CYP1B1ALDH1A1HPGDKMT2A | |
| SCHEMBL20420727 | 0.75 | TNKS (0.58) | ABCG2CYP1A1CYP1B1HPGDKMT2A | |
| SCHEMBL20428325 | 0.74 | HPGD (0.61) | ABCG2CYP1B1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3354648-B1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-108349959-B | 4-substituted coumarin derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| EP-3354648-A1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| EP-3354648-A1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| CN-108349959-A | The coumarin derivative and its preparation method and application of 4 substitutions | 贵州百灵企业集团制药股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | MAP4, TUBA3C, ABCC1 | PTGES 3771/4885ALOX5 3687/4885LCK 1357/4885 |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | MAP4, TUBA3C, ABCC1 | PTGES 3771/4885ALOX5 3687/4885LCK 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.